{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'An Open-Label, Randomized Phase 3 Study to Evaluate', 'Enfortumab Vedotin VS Chemotherapy in Subjects with', 'Previously Treated Locally Advanced or Metastatic', 'Urothelial Cancer (EV-301)', 'ISN/Protocol 7465-CL-0301', 'Version 4.0', 'Incorporating Substantial Amendment 3 [See Section', '13', '14 Sep 2020', 'NCT03474107', 'IND 116360', 'EudraCT 2017-003344-21', 'Sponsor:', 'Astellas Pharma Global Development, Inc. (APGD)', '1 Astellas Way', 'Northbrook, IL 60062', 'Protocol History:', 'Version 1.0 Original [20Dec2017]', 'Version 2.0 Incorporating Substantial Amendment 1 [22Aug2018', 'Version 3.0 Incorporating Substantial Amendment 2 11Dec2019]', 'The information contained in this document is supplied as a background for clinical investigations. This document contains', 'confidential information which is the intellectual property of Astellas. By accepting or reviewing this document, you agree', 'to hold this information in confidence and not copy or disclose it to others or use it for unauthorized purposes except (1) as', 'otherwise agreed to in writing; (2) where required by applicable law; (3) where disclosure is directly related to the care and', \"safety of the research participant; and (4) where disclosure of such information is made to a member of the investigator's\", 'team who agrees to hold this information in confidence.', '14 Sep 2020', 'Astellas', 'Page 1 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Table of Contents', 'I.', 'SIGNATURES', '8', 'II.', \"CONTACT DETAILS OF KEY SPONSOR'S PERSONNEL\", '12', 'III.', 'LIST OF ABBREVIATIONS AND DEFINITION OF KEY TERMS', '13', 'IV.', 'SYNOPSIS', '17', 'V.', 'FLOW CHART AND SCHEDULE OF ASSESSMENTS', '31', '1', 'INTRODUCTION', '38', '1.1', 'Urothelial Cancer', '38', '1.2', 'Nonclinical and Clinical Data', '39', '1.2.1', 'Enfortumab Vedotin Nonclinical Pharmacology', '39', '1.2.2', 'Enfortumab Vedotin', '39', '1.2.3', 'Enfortumab Vedotin Nonclinical Toxicology', '39', '1.2.4', 'Clinical Data', '41', '1.3', 'Summary of Key Safety Information for Enfortumab Vedotin', '42', '1.4', 'Risk Benefit Assessment', '42', '2', 'STUDY OBJECTIVE(S), DESIGN AND ENDPOINTS', '43', '2.1', 'Study Objective(s)', '43', '2.1.1', 'Primary Objective', '43', '2.1.2', 'Secondary Objectives', '43', '2.1.3', 'Exploratory Objectives', '43', '2.2', 'Study Design and Dose Rationale', '44', '2.2.1', 'Study Design', '44', '2.2.2', 'Dose Rationale', '46', '2.3', 'Endpoints', '47', '2.3.1', 'Primary Enppoints', '47', '2.3.2', 'Secondary Endpoints', '47', '2.3.3', 'Exploratory Endpoints', '47', '3', 'STUDY POPULATION', '48', '3.1', 'Selection of Study Population', '48', '3.2', 'Inclusion Criteria', '48', '3.3', 'Exclusion Criteria', '51', '4', 'TREATMENT(S)', '53', '14 Sep 2020', 'Astellas', 'Page 2 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '4.1', 'Identification of Investigational Product(s)', '53', '4.1.1', 'Study Drug(s)', '53', '4.1.2', 'Comparative Drug(s)', '53', '4.2', 'Packaging and Labeling', '53', '4.3', 'Study Drug Handling', '54', '4.4', 'Blinding', '54', '4.5', 'Assignment and Allocation', '54', '5', 'TREATMENTS AND EVALUATION', '55', '5.1', 'Dosing and Administration of Study Drug(s) and Other Medication(s)', '55', '5.1.1', 'Dose/Dose Regimen and Administration Period', '55', '5.1.1.1', 'Enfortumab Vedotin', '55', '5.1.1.2', 'Comparative Drug(s)', '55', '5.1.2', 'Increase or Reduction in Dose of the Study Drug(s)', '57', '5.1.2.1', 'Enfortumab Vedotin', '57', '5.1.2.2', 'Dose Modification for treatment with Docetaxel, Paclitaxel or', 'Vinflunine', '60', '5.1.2.3', 'Docetaxel Dose Modifications', '62', '5.1.2.4', 'Vinflunine Dose Modifications', '63', '5.1.2.5', 'Paclitaxel Dose Modifications', '64', '5.1.3', 'Previous and Concomitant Treatment (Medication and Nonmedication', 'Therapy)', '65', '5.1.4', 'Treatment Compliance', '66', '5.2', 'Demographics and Baseline Characteristics', '66', '5.2.1', 'Demographics', '66', '5.2.2', 'Medical History', '66', '5.2.3', 'Diagnosis of the Target Disease, Severity, and Duration of Disease', '66', '5.2.4', 'Performance Status', '67', '5.3', 'Efficacy Assessments', '67', '5.3.1', 'Evaluation of Target Lesions', '68', '5.3.1.1', 'Complete Response', '68', '5.3.1.2', 'Partial Response', '68', '5.3.1.3', 'Stable Disease', '68', '5.3.1.4', 'Progressive Disease', '68', '5.3.2', 'Evaluation of Nontarget Lesions', '68', '5.3.2.1', 'Complete Response', '68', '14 Sep 2020', 'Astellas', 'Page 3 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}